Protalix (PLX) Director Gwen Melincoff Receives 25,500-Share Award

What Happened

• Gwen A. Melincoff, a director of Protalix BioTherapeutics (PLX), was granted a total of 25,500 derivative awards on September 3, 2026 (17,000 + 8,500). The awards were recorded at $0.00 per share (no cash paid) and are reported as restricted stock units (RSUs)/derivative securities that represent the right to receive one share per RSU upon vesting.

Key Details

• Transaction date: 2026-09-03; filing date: 2026-09-04 (reported the next day).
• Amounts: 17,000 RSUs and 8,500 RSUs, total 25,500 RSUs; price reported $0.00 (award/grant).
• Vesting: Per footnotes, the RSUs vest in 12 equal quarterly installments commencing on the grant date (i.e., quarterly over three years).
• Each RSU converts to one share of common stock upon vesting (per footnote).
• Report does not disclose total shares owned after the grant in the provided summary.
• Footnote also lists existing outstanding options held by the insider (several option grants with various exercise prices and expirations) that were not part of this award.
• Filing appears timely (next-day report); no late filing indicated.

Context

• These are equity awards (RSUs), not open-market purchases or option exercises. RSUs do not deliver shares until they vest, so this is a future issuance rather than an immediate stock purchase or sale.
• Awards recorded at $0.00 are standard for compensation grants and do not indicate a cash transaction.